Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Racial disparities in childhood obesity have risen due to social determinants, food insecurity, and systemic barriers, ...

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

Air pollution exposure, both before and after birth, significantly escalates the risk of respiratory infections in children.

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic ...

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial ...

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.